Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871776 · ClinicalTrials.gov registry record · NA
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
A NA study of COVID-19 and Vaccine Refusal, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 3,671
- Enrollment target
- 1
- Study location
NCT04871776: Completed NA study of COVID-19 and Vaccine Refusal, sponsored by Brigham and Women's Hospital.
NCT04871776 is a NA study of COVID-19 and Vaccine Refusal that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 3,671 participants, below the 38,453-participant average among 298 other COVID-19 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04871776, a NA study of COVID-19 and Vaccine Refusal, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,671 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.
Primary Outcome
Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Messaging informed by construal level theory
Study Locations (1)
Massachusetts
- Mass General Brigham - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,671 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2022-08-17 |
| Phase | NA |
What the finished NCT04871776 record still lists
NCT04871776 is an interventional study that assigns participants to a tested intervention. Its 3,671 participants enrollment target places it among the larger protocols in the corpus, below the 38,453-participant average among 298 other COVID-19 trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT04871776 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04871776 about?
NCT04871776 is a clinical study titled "Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19". This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upco...
What is the current status of trial NCT04871776?
This trial is currently completed. It is a NA study. The enrollment target is 3,671 participants. The study started on 2022-02-18. Estimated completion is 2022-08-17.
What conditions does trial NCT04871776 study?
This clinical trial studies the following conditions: COVID-19, Vaccine Refusal.
What interventions are being tested in trial NCT04871776?
The interventions under investigation include: Usual Care (BEHAVIORAL), Messaging informed by construal level theory (BEHAVIORAL).
Who is sponsoring clinical trial NCT04871776?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871776 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04871776's enrollment target sits among peer trials
3,671 34th of 298 higher than 265 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI